Share

April 30, 2019; 92 (18) Editorial

Naproxen for presymptomatic Alzheimer disease

Is this the end, or shall we try again?

Linda A. Hershey, Richard B. Lipton
First published April 5, 2019, DOI: https://doi.org/10.1212/WNL.0000000000007233
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
184

Share

Article Information

vol. 92 no. 18 829-830
DOI: 
https://doi.org/10.1212/WNL.0000000000007233
PubMed: 
30952790
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 5, 2019.

Article Versions

Copyright & Usage: 
© 2019 American Academy of Neurology

Author Disclosures

    1. Linda A. Hershey, MD, PhD and
    2. Richard B. Lipton, MD
  1. Linda A. Hershey, MD, PhD and
    2. Scientific Advisory Boards:

    1. I sit on the Long Term Care Stakeholders Committee for the Oklahoma Foundation for Medical Quality (OFMQ); I was recently appointed to serve on the Mild Cognitive Impairment Quality Measurement Work Group for the AAN Institute.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. I have served on the editorial board of Neurology from 2011-present. I am on the editorial board of JSM Alzheimer's Disease & Related Dementia, 2014-present. I am on the editorial board of J Neuroscience & Cognitive Studies, 2017-present.

    Patents:

    1. NONE

    Publishing Royalties:

    1. Since 2015, I have received annual royalties for writing reviews for MedLink Neurology about these 3 topics: a) Memory Loss b) Cognitive and behavioral changes in PSP c) Sleep and dementia In 2018, I received an honorarium for reviewing a paper about Parkinson disease from the Annals Internal Medicine.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I served on the Network of Experts (about Alzheimer disease) for the FDA in 2018.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. I held an endowed chair at OU from 2010-2015: Ethelyn McElwee Endowed Chair in Alzheimer's Disease Research, University of Oklahoma Health Sciences Center and was the Director of Dementia & Behavioral Neurology at OU Physicians. I am now retired from practice, but I still teach medical students, grad students and residents at OU.

    Research Support, Commercial Entities:

    1. Dr. Hershey was the site PI for two Forum Pharmaceuticals studies of a new drug for Alzheimer's disease (2014-2016).

    Research Support, Government Entities:

    1. Dr. Hershey was co-investigator (5% effort) on a translational research study from the NIH(8UL1TR000041) about delivering the STOMP intervention in the home environment, 2013-14.

    Research Support, Academic Entities:

    1. She is the co-PI (5% effort)on an OUHSC VP for Research study to examine memory consolidation in elders with aMCI, 2014-2015. She was the co-PI for the Singer Seed Grant from the Oklahoma College of Nursing, 2014-2015.

    Research Support, Foundations and Societies:

    1. Dr. Hershey was co-investigator on an Alzheimer's Association grant to study ways to reduce disability in dementia patients by using O.T. interventions, 2014-2016.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. I gave expert testimony to two sets of lawyers during 2016 concerning a stroke pt of mine. The proceeds for this testimony went to my department.

  2. Richard B. Lipton, MD
    3. Scientific Advisory Boards:

    1. Allergan, e-Neura, Merck

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy?s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta

    Editorial Boards:

    1. Neurology, Editorial Board, 2017-

    Patents:

    1. NONE

    Publishing Royalties:

    1. Wolff's Headache, 8th Edition, Oxford University Press; Informa

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy?s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Vedanta Research Migraine epidemiology and Progression June 2010 - present Boston Scientific Occipital Nerve Stimulation in Migraine March 2013 - present ElectroCore Vagal Nerve Stimulation for Migraine and Cluster May 2013 Novartis Sleep and Migraine September 2012 - present Allergan Botox in Migraine April 2012 - present Allergan Chronic Migraine Epidemiology and Outcome Study January 2012 - present

    Research Support, Government Entities:

    1. NIH/NIA 2PO1 AG003949 Einstein Aging Study 9/1/16-5/31/21 Role: Principle Investigator NIH R01AG042595 Stress, cognition, repetitive unconstructive thoughts and inflammatory markers 7/1/12-6/30/17 Role: Investigator NIH/NINDS 1U10NS077308-01 Einstein Center for Excellence for Clinical Trials in Neuroscience 9/30/11-8/31/18 Role: Co-PI NIH/NINDS R01 NS082432-03 Brain injury due to soccer heading and opportunities for its mitigation 4/1/13-3/31/18 Role: Investigator NINDS/NIH 1R01AG048642 Study of Latinos-Investigation of Neurocognitive Aging 9/1/15-4/30/17 Role: Co-Investigator 1K23NS096107-01 Clinical Decision Support for Patient Migraine Management 4/01/16-3/31/21 Role: Primary Mentor 1K23AG049466-01 The relation of migraine to daily hormone patterns and menopausal stage 9/30/16-5/31/17 Role: Primary Mentor 1K01AG054700-01 Application of latent and integrative approaches to understand the spectrum of cognitive aging 3/15/17-2/28/22 Role: Primary Mentor

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. S & L Marx Foundation Alzheimer's Research Czap Foundation Alzheimer's Research

    Stock/Stock Options/Board of Directors Compensation:

    1. eNeura Pharma; Biohaven Inc.

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. Oxford University Press; Baxter Publishing

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (L.A.H.), University of Oklahoma Health Sciences Center, Oklahoma City; and Departments of Neurology, Psychiatry & Behavioral Sciences, and Epidemiology & Population Health (R.B.L.), Albert Einstein College of Medicine, Bronx, NY.
  1. Correspondence
    Dr. Hershey linda-hershey{at}ouhsc.edu
View Full Text

Article usage

Article usage: April 2019 to March 2023

AbstractFullPdfSource
Apr 20197163355Highwire
May 20192593323Highwire
Jun 20191171210Highwire
Jul 20191321011Highwire
Aug 20198544Highwire
Sep 201945127Highwire
Oct 20199743Highwire
Nov 20198944Highwire
Dec 20194232Highwire
Jan 2020129615Highwire
Feb 20204355Highwire
Mar 20206142Highwire
Apr 20209652Highwire
May 20209012Highwire
Jun 20207835Highwire
Jul 20205602Highwire
Aug 20206802Highwire
Sep 20207420Highwire
Oct 20206411Highwire
Nov 20205522Highwire
Dec 20204300Highwire
Jan 20213401Highwire
Feb 20214710Highwire
Mar 20214313Highwire
Apr 20213510Highwire
May 20215020Highwire
Jun 20213723Highwire
Jul 20214913Highwire
Aug 20213942Highwire
Sep 20214432Highwire
Oct 20213210Highwire
Nov 20213410Highwire
Dec 20212910Highwire
Jan 20224401Highwire
Feb 20223700Highwire
Mar 20222600Highwire
Apr 20224242Highwire
May 20226100Highwire
Jun 20221911Highwire
Jul 20223605Highwire
Aug 20221410Highwire
Sep 20225600Highwire
Oct 20223611Highwire
Nov 20225500Highwire
Dec 20227700Highwire
Jan 20234212Highwire
Feb 20232911Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles